002393 力生制药
已收盘 11-06 15:00:00
资讯
新帖
简况
力生制药:公司主业仍聚焦医药健康
证券之星 · 11-03 20:52
力生制药:公司主业仍聚焦医药健康
力生制药:相关资本运作事项需严格履行国资审批及信息披露程序
证券之星 · 11-03 20:48
力生制药:相关资本运作事项需严格履行国资审批及信息披露程序
力生制药:社区健康驿站及三鱼数智尚在培育阶段
证券之星 · 11-03
力生制药:社区健康驿站及三鱼数智尚在培育阶段
力生制药(002393)11月2日主力资金净买入61.10万元
证券之星 · 11-03
力生制药(002393)11月2日主力资金净买入61.10万元
股市必读:力生制药(002393)11月2日董秘有最新回复
证券之星 · 11-03
股市必读:力生制药(002393)11月2日董秘有最新回复
力生制药(002393)披露2026年三季度报告,10月26日股价下跌0.53%
证券之星 · 10-26
力生制药(002393)披露2026年三季度报告,10月26日股价下跌0.53%
力生制药:仿制药行业近年来受到药品集中带量采购常态化、市场竞争加剧等因素影响
证券之星 · 10-26
力生制药:仿制药行业近年来受到药品集中带量采购常态化、市场竞争加剧等因素影响
天津发展(00882):力生制药前三季度归母净利润7851万元 同比减少78.82%
智通财经 · 10-26
天津发展(00882):力生制药前三季度归母净利润7851万元 同比减少78.82%
图解力生制药三季报:第三季度单季净利润同比下降99.34%
证券之星 · 10-25
图解力生制药三季报:第三季度单季净利润同比下降99.34%
力生制药:三鱼数智目前尚处在初创与场景打磨阶段
证券之星 · 10-23
力生制药:三鱼数智目前尚处在初创与场景打磨阶段
股市必读:力生制药(002393)10月21日董秘有最新回复
证券之星 · 10-22
股市必读:力生制药(002393)10月21日董秘有最新回复
力生制药:土霉素片说明书适应症包含鼠疫
证券之星 · 10-21
力生制药:土霉素片说明书适应症包含鼠疫
力生制药:公司将严格按照国资监管要求、公司章程履行法定程序
证券之星 · 10-20
力生制药:公司将严格按照国资监管要求、公司章程履行法定程序
力生制药:公司三季报编制、审核流程严格执行信息披露相关法规
证券之星 · 10-20
力生制药:公司三季报编制、审核流程严格执行信息披露相关法规
力生制药最新公告:沙库巴曲缬沙坦钠片通过上市许可申请
证券之星 · 10-19
力生制药最新公告:沙库巴曲缬沙坦钠片通过上市许可申请
力生制药:公司自研 1 类及改良型新药围绕慢病等重点领域布局
证券之星 · 10-19
力生制药:公司自研 1 类及改良型新药围绕慢病等重点领域布局
力生制药:公司及下属子公司暂无专门获批用于鼠疫预防或治疗适应症的药品
证券之星 · 10-19
力生制药:公司及下属子公司暂无专门获批用于鼠疫预防或治疗适应症的药品
股市必读:力生制药(002393)10月13日董秘有最新回复
证券之星 · 10-14
股市必读:力生制药(002393)10月13日董秘有最新回复
力生制药:公司经营管理层始终围绕既定战略扎实推进各项经营工作
证券之星 · 10-13
力生制药:公司经营管理层始终围绕既定战略扎实推进各项经营工作
力生制药:公司与央广云听的有声剧合作主要用于老字号品牌及健康科普传播
证券之星 · 10-12
力生制药:公司与央广云听的有声剧合作主要用于老字号品牌及健康科普传播
加载更多
公司概况
公司名称:
天津力生制药股份有限公司
所属行业:
医药制造业
上市日期:
2010-04-23
主营业务:
天津力生制药股份有限公司的主营业务是医药产品研发、生产和销售。公司的主要产品是寿比山吲达帕胺片、三鱼氨酚咖匹林片、希福尼头孢地尼分散片、友好麻仁软胶囊、生化氢化可的松琥珀酸钠冻干粉针、碳酸氢钠片、盖胃平片、麻仁润肠丸、虎力散片。力生制药作为国家高新技术企业、国家企业技术中心、国家级绿色工厂,成功获评“医药医疗行业ESG绩效TOP20”,先后荣获中国上市公司董事会金圆桌奖、年度ESG价值传递奖、医药行业数字化转型标杆等多项荣誉。
发行价格:
45.00
{"stockData":{"symbol":"002393","market":"SZ","secType":"STK","nameCN":"力生制药","latestPrice":12.93,"timestamp":1793948625000,"preClose":13.15,"halted":0,"volume":1624660,"delay":0,"changeRate":-0.0167,"floatShares":300000000,"shares":308000000,"eps":0.4024,"marketStatus":"已收盘","change":-0.22,"latestTime":"11-06 15:00:00","open":13.02,"high":13.05,"low":12.9,"amount":21048600,"amplitude":0.0114,"askPrice":12.96,"askSize":35,"bidPrice":12.93,"bidSize":82,"shortable":0,"etf":0,"ttmEps":0.4024,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":5,"adr":0,"adjPreClose":13.15,"symbolType":"stock","openAndCloseTimeList":[[1793928600000,1793935800000],[1793941200000,1793948400000]],"highLimit":14.47,"lowLimit":11.84,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":308293069,"isCdr":false,"pbRate":0.9,"roa":"--","peRate":32.132207,"roe":"1.75%","epsLYR":1.62,"committee":0.478382,"marketValue":3986000000,"turnoverRate":0.0054,"status":1,"floatMarketCap":3882000000},"requestUrl":"/m/hq/s/002393","defaultTab":"news","newsList":[{"id":"2680294557","title":"力生制药:公司主业仍聚焦医药健康","url":"https://stock-news.laohu8.com/highlight/detail?id=2680294557","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680294557?lang=zh_cn&edition=full","pubTime":"2026-11-03 20:52","pubTimestamp":1793710358,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药11月03日在投资者关系平台上答复投资者关心的问题。目前公司暂无并购切入文娱赛道的计划,对外投资、并购将围绕医药主业战略统筹推进。如发生需披露的重大事项,公司将及时公告,敬请注意投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300041046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680572992","title":"力生制药:相关资本运作事项需严格履行国资审批及信息披露程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2680572992","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680572992?lang=zh_cn&edition=full","pubTime":"2026-11-03 20:48","pubTimestamp":1793710139,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药11月03日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘:公司作为国资委改革标的股,市值仅40亿左右,且严重破净!在国资委市值考核下,大股东与管理层有无具体的问责指标?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300040461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0188","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680715459","title":"力生制药:社区健康驿站及三鱼数智尚在培育阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2680715459","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680715459?lang=zh_cn&edition=full","pubTime":"2026-11-03 11:33","pubTimestamp":1793676799,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药(002393)11月03日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘:关注到报道提及公司布局“AI+慢病数字服务”。请问:“社区健康驿站”已落地几家?三鱼数智用户及收入如何?该服务是独立收费还是捆绑卖药?何时能实现盈亏平衡?谢谢。力生制药回复:尊敬的投资者您好,感谢关注。社区健康驿站及三鱼数智尚在培育阶段,暂未形成规模化用户及收入。慢病数字服务不捆绑售药,盈亏平衡时点暂无法预判,如取得重大进展公司将依规披露,谢谢。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300018407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002393","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680902287","title":"力生制药(002393)11月2日主力资金净买入61.10万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680902287","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680902287?lang=zh_cn&edition=full","pubTime":"2026-11-03 09:47","pubTimestamp":1793670432,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月2日收盘,力生制药报收于12.47元,下跌0.48%,换手率0.75%,成交量2.24万手,成交额2792.56万元。近5日资金流向一览见下表:力生制药融资融券信息显示,融资方面,当日融资买入301.28万元,融资偿还203.55万元,融资净买入97.74万元。力生制药主营业务:从事医药产品研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300014896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002393","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680767216","title":"股市必读:力生制药(002393)11月2日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2680767216","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680767216?lang=zh_cn&edition=full","pubTime":"2026-11-03 03:30","pubTimestamp":1793647836,"startTime":"0","endTime":"0","summary":"截至2026年11月2日收盘,力生制药报收于12.47元,下跌0.48%,换手率0.75%,成交量2.24万手,成交额2792.56万元。董秘最新回复投资者: 董秘您好:感谢对10月26日提问的回复,但公司对“引入战投混改”及“大股东作为”等核心建议避而不谈,难以打消投资者的深切忧虑。公司管理层始终本着对全体股东负责的态度,勤勉尽责开展各项经营管理工作。截至目前,公司不存在应披露而未披露的重大事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300005518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","002393","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678816488","title":"力生制药(002393)披露2026年三季度报告,10月26日股价下跌0.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678816488","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678816488?lang=zh_cn&edition=full","pubTime":"2026-10-26 18:18","pubTimestamp":1793009937,"startTime":"0","endTime":"0","summary":"截至2026年10月26日收盘,力生制药报收于13.1元,较前一交易日下跌0.53%,最新总市值为40.39亿元。该股当日开盘12.93元,最高13.12元,最低12.64元,成交额达2914.54万元,换手率为0.75%。公司于2026年10月26日披露《2026年三季度报告》。报告显示,本报告期营业收入246,382,626.45元,比上年同期下降10.66%;归属于上市公司股东的净利润183,947.10元,比上年同期下降99.34%。年初至报告期末,营业收入888,015,988.08元,同比下降11.84%;归属于上市公司股东的净利润78,509,979.37元,同比下降78.82%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600025807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","002393","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678150014","title":"力生制药:仿制药行业近年来受到药品集中带量采购常态化、市场竞争加剧等因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2678150014","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678150014?lang=zh_cn&edition=full","pubTime":"2026-10-26 16:00","pubTimestamp":1793001639,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药10月26日在投资者关系平台上答复投资者关心的问题。仿制药行业近年来受到药品集中带量采购常态化、市场竞争加剧等因素影响,行业整体经营压力有所上升,这是业内企业共同面对的外部环境。公司管理层始终勤勉尽责,围绕主业稳步开展经营工作,在研发创新、产品结构优化、市场拓展、成本与效率管理等方面持续推进。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600018727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002393","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678358156","title":"天津发展(00882):力生制药前三季度归母净利润7851万元 同比减少78.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678358156","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678358156?lang=zh_cn&edition=full","pubTime":"2026-10-26 12:18","pubTimestamp":1792988299,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天津发展(00882)发布力生制药截至2026年9月30日止九个月业绩,营业总收入8.88亿元人民币,同比减少11.84%;归属于母公司所有者的净利润7851万元,同比减少78.82%;基本每股收益0.25元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002393","00882"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678668187","title":"图解力生制药三季报:第三季度单季净利润同比下降99.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678668187","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678668187?lang=zh_cn&edition=full","pubTime":"2026-10-25 16:37","pubTimestamp":1792917452,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药2026年三季报显示,前三季度公司主营收入8.88亿元,同比下降11.84%;归母净利润7851.0万元,同比下降78.82%;扣非净利润6598.05万元,同比下降47.94%;其中2026年第三季度,公司单季度主营收入2.46亿元,同比下降10.66%;单季度归母净利润18.39万元,同比下降99.34%;单季度扣非净利润-106.15万元,同比下降104.72%;负债率14.94%,投资收益1100.18万元,财务费用-1023.23万元,毛利率51.64%。财报数据概要请见下图:本文数据来源于力生制药2026年三季报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102500004370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677913450","title":"力生制药:三鱼数智目前尚处在初创与场景打磨阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2677913450","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677913450?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:54","pubTimestamp":1792716856,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药10月23日在投资者关系平台上答复投资者关心的问题。AI技术在降本增效方面有无量化指标?后续如有达到披露标准的重大进展,公司将及时公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300008592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0028","002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677560117","title":"股市必读:力生制药(002393)10月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2677560117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677560117?lang=zh_cn&edition=full","pubTime":"2026-10-22 03:32","pubTimestamp":1792611131,"startTime":"0","endTime":"0","summary":"截至2026年10月21日收盘,力生制药报收于13.5元,下跌0.59%,换手率0.41%,成交量1.22万手,成交额1661.21万元。但您此前回复“暂无专门获批用于鼠疫预防或治疗适应症的药品”。土霉素片说明书适应症包含鼠疫,但它是广谱抗生素,并非鼠疫专用治疗药物,不可用于预防,患者用药请谨遵医嘱。当日关注点交易信息汇总:10月21日主力资金净流出88.25万元,占总成交额5.31%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200003327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677648052","title":"力生制药:土霉素片说明书适应症包含鼠疫","url":"https://stock-news.laohu8.com/highlight/detail?id=2677648052","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677648052?lang=zh_cn&edition=full","pubTime":"2026-10-21 09:00","pubTimestamp":1792544457,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药10月21日在投资者关系平台上答复投资者关心的问题。土霉素片说明书适应症包含鼠疫,但它是广谱抗生素,并非鼠疫专用治疗药物,不可用于预防,患者用药请谨遵医嘱。提醒投资者理性投资,注意风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100007999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002393","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676657715","title":"力生制药:公司将严格按照国资监管要求、公司章程履行法定程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2676657715","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676657715?lang=zh_cn&edition=full","pubTime":"2026-10-20 15:03","pubTimestamp":1792479790,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药10月20日在投资者关系平台上答复投资者关心的问题。在当前业绩低迷/转型期,公司在管理层“干部年轻化”及后备人才梯队建设是否已有规划?谢谢力生制药回复:尊敬的投资者您好。关于董事长换届相关安排,公司将严格按照国资监管要求、公司章程履行法定程序。公司高度重视干部梯队建设,持续推进干部结构优化,落实干部年轻化导向,多渠道储备、选拔骨干人才,根据经营发展需要统筹管理团队配置。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000017354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","002393","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676657712","title":"力生制药:公司三季报编制、审核流程严格执行信息披露相关法规","url":"https://stock-news.laohu8.com/highlight/detail?id=2676657712","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676657712?lang=zh_cn&edition=full","pubTime":"2026-10-20 15:03","pubTimestamp":1792479790,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药10月20日在投资者关系平台上答复投资者关心的问题。公司三季报编制、审核流程严格执行信息披露相关法规,对财务数据实施内幕信息管理与保密管控,落实内幕知情人登记,截至目前未发现信息提前泄露情形。公司将严格按时披露定期报告,保障全体投资者平等获取信息,持续做好内幕交易防控工作。请以公司公开披露信息为准,理性投资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000017355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002393","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676105509","title":"力生制药最新公告:沙库巴曲缬沙坦钠片通过上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2676105509","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676105509?lang=zh_cn&edition=full","pubTime":"2026-10-19 16:37","pubTimestamp":1792399020,"startTime":"0","endTime":"0","summary":"力生制药(002393.SZ)公告称,公司收到国家药品监督管理局颁发的沙库巴曲缬沙坦钠片《药品注册证书》,该药品通过上市许可申请。药品规格为以沙库巴曲缬沙坦计100mg,注册分类为化学药品,用于射血分数降低的慢性心力衰竭成人患者及原发性高血压治疗。该药品获批将进一步丰富公司循环系统药物产品线,提高市场竞争力,视同通过一致性评价。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900020615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0239","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676572197","title":"力生制药:公司自研 1 类及改良型新药围绕慢病等重点领域布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2676572197","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676572197?lang=zh_cn&edition=full","pubTime":"2026-10-19 11:36","pubTimestamp":1792380991,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药10月19日在投资者关系平台上答复投资者关心的问题。谢谢力生制药回复:尊敬的投资者您好,公司自研 1 类及改良型新药围绕慢病等重点领域布局,各项目分处在不同研发节点;抗抑郁相关管线处于前期研发阶段。新药研发存在不确定性,相关具体适应症、细分阶段等信息暂不便于披露,若项目达到披露标准,公司将及时公告。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900010754.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","002393","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676572960","title":"力生制药:公司及下属子公司暂无专门获批用于鼠疫预防或治疗适应症的药品","url":"https://stock-news.laohu8.com/highlight/detail?id=2676572960","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676572960?lang=zh_cn&edition=full","pubTime":"2026-10-19 11:33","pubTimestamp":1792380785,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药(002393)10月19日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘:近期鼠疫防治受到关注。请问公司及下属子公司是否拥有用于预防或治疗鼠疫的药物?若有,烦请说明具体品种、批准文号、目前是否正常生产及产能情况;若没有,也请明确告知。谢谢。力生制药回复:尊敬的投资者您好,公司及下属子公司暂无专门获批用于鼠疫预防或治疗适应症的药品。感谢您的关注。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900010530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002393","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675361049","title":"股市必读:力生制药(002393)10月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2675361049","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675361049?lang=zh_cn&edition=full","pubTime":"2026-10-14 02:56","pubTimestamp":1791917770,"startTime":"0","endTime":"0","summary":"截至2026年10月13日收盘,力生制药报收于13.99元,下跌0.21%,换手率0.64%,成交量1.91万手,成交额2651.42万元。公司将依规做好信息披露工作,积极维护全体投资者合法权益。当日关注点交易信息汇总:10月13日主力资金净流入237.63万元,占总成交额8.96%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400002050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002393","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675331056","title":"力生制药:公司经营管理层始终围绕既定战略扎实推进各项经营工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2675331056","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675331056?lang=zh_cn&edition=full","pubTime":"2026-10-13 16:18","pubTimestamp":1791879489,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药10月13日在投资者关系平台上答复投资者关心的问题。公司将依规做好信息披露工作,积极维护全体投资者合法权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300026198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674035824","title":"力生制药:公司与央广云听的有声剧合作主要用于老字号品牌及健康科普传播","url":"https://stock-news.laohu8.com/highlight/detail?id=2674035824","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674035824?lang=zh_cn&edition=full","pubTime":"2026-10-12 15:06","pubTimestamp":1791788783,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药10月12日在投资者关系平台上答复投资者关心的问题。公司与央广云听的有声剧合作主要用于老字号品牌及健康科普传播,属于品牌营销。后续公司将审慎探索 IP 内容营销,若有达到披露标准的重大合作,将及时公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200014331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002393","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793963674859,"stockEarnings":[{"period":"1week","weight":0.0478},{"period":"1month","weight":-0.0661},{"period":"3month","weight":-0.1103},{"period":"6month","weight":-0.203},{"period":"1year","weight":-0.237},{"period":"ytd","weight":-0.2426}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0396},{"period":"3month","weight":-0.0635},{"period":"6month","weight":-0.1172},{"period":"1year","weight":-0.0704},{"period":"ytd","weight":-0.0703}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"天津力生制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"22165人(较上一季度增加3.53%)","perCapita":"13544股","listingDate":"2010-04-23","address":"天津市西青区西青经济技术开发区赛达北一道16号","registeredCapital":"30829万元","survey":" 天津力生制药股份有限公司的主营业务是医药产品研发、生产和销售。公司的主要产品是寿比山吲达帕胺片、三鱼氨酚咖匹林片、希福尼头孢地尼分散片、友好麻仁软胶囊、生化氢化可的松琥珀酸钠冻干粉针、碳酸氢钠片、盖胃平片、麻仁润肠丸、虎力散片。力生制药作为国家高新技术企业、国家企业技术中心、国家级绿色工厂,成功获评“医药医疗行业ESG绩效TOP20”,先后荣获中国上市公司董事会金圆桌奖、年度ESG价值传递奖、医药行业数字化转型标杆等多项荣誉。","listedPrice":45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"力生制药(002393)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供力生制药(002393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"力生制药,002393,力生制药股票,力生制药股票老虎,力生制药股票老虎国际,力生制药行情,力生制药股票行情,力生制药股价,力生制药股市,力生制药股票价格,力生制药股票交易,力生制药股票购买,力生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"力生制药(002393)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供力生制药(002393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}